OncoMatch/Clinical Trials/NCT06742463
VHAG in Treating R/R T-ALL/LBL
Is NCT06742463 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and homoharringtonine for acute t lymphpblastic leukemia/lymphoma.
Treatment: Venetoclax · homoharringtonine · Cytarabine (Ara-C) · G-CSF — Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages. After induction chemotherapy and consolidation chemotherapy, there are still about 30% of patients who cannot achieve complete remission of clinical symptoms or negative MRD. This is also an important factor for the recurrence of ALL patients. In addition, most relapsed T-ALL/LBL patients relapse during first-line treatment. Once the disease relapses, it is difficult to cure for most young and adult patients, and the overall survival rate of patients is less than 10%.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine > 1.5 ULN
Liver function
Serum total bilirubin > 1.5 ULN (upper limit of normal); ALT or AST > 2.5 ULN
Cardiac function
Cardiac ultrasound LVEF < 45%
Serum total bilirubin > 1.5 ULN (upper limit of normal); ALT or AST > 2.5 ULN; serum creatinine > 1.5 ULN; Cardiac ultrasound LVEF < 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify